# Osimertinib Mesylate (Tagrisso)

Source: https://ourhealthnetwork.com/drugs/osimertinib-mesylate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Osimertinib Mesylate?

Osimertinib Mesylate (brand name: Tagrisso) is a kinase inhibitor. It is prescribed to treat carcinoma, non-small-cell lung. Across the United States, 2,000 doctors prescribe Osimertinib to approximately 2,000 Medicare patients.

## Brand names

Tagrisso

## Indications

Osimertinib Mesylate is prescribed for the treatment of carcinoma and non-small-cell lung.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Non-Small-Cell Lung](https://ourhealthnetwork.com/conditions/non-small-cell-lung)

## Mechanism of action

Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions) at approximately 9-fold lower concentrations than wild-type. Two pharmacologically-active metabolites (AZ7550 and AZ5104 circulating at approximately 10% of the parent) with similar inhibitory profiles to osimertinib have b

## Drug classification

- Established Pharmacologic Class: Kinase Inhibitor [EPC]
- Mechanism of Action class: Kinase Inhibitors [MoA]
- Route of administration: ORAL

## Common side effects

and fatigue, and neutropenia, anemia, dry skin, lymphopenia, musculoskeletal pain, nail toxicity, o monotherapy were diarrhea

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)